Related Experiment Video
Updated: Mar 11, 2026
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.8K
Pediatric multiple sclerosis: updates in epidemiology, clinical features and management
1Assistant Professor of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
Neurodegenerative Disease Management
|November 23, 2016
Summary
Consensus definitions have improved the recognition and understanding of pediatric multiple sclerosis (MS). Research is advancing on genetic and environmental factors, with new treatments nearing completion.
Area of Science:
- Pediatric Neurology
- Immunology
- Neuroscience
Background:
- Acute demyelinating syndromes in children are increasingly recognized as pediatric multiple sclerosis (MS).
- Pediatric MS accounts for an estimated 2-10% of all MS cases.
- Understanding of pediatric MS pathogenesis, epidemiology, and treatment has significantly improved.
Purpose of the Study:
- To summarize the current understanding of pediatric multiple sclerosis.
- To highlight advancements in research and treatment for pediatric MS.
- To emphasize the need for continued research and international collaboration.
Main Methods:
- Review of current literature and consensus definitions for pediatric demyelinating syndromes.
- Analysis of identified genetic and environmental risk factors in pediatric MS pathogenesis.
- Overview of ongoing clinical trials for disease-modifying therapies in children.
Main Results:
- Consensus definitions have enhanced the recognition and study of pediatric MS.
- Multiple genetic and environmental risk factors are implicated in pediatric MS, requiring further investigation into their interplay.
- Clinical trials for novel disease-modifying therapies in pediatric MS are approaching completion.
Conclusions:
- Improved understanding and recognition of pediatric MS due to consensus definitions.
- Emerging therapies offer promise but present new challenges.
- International collaboration is crucial for advancing research in this rare condition.
Related Concept Videos
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
306
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
605
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
346
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
346
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
411
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411